Search

Your search keyword '"Cerhan, James R."' showing total 3,102 results
Start Over Author "Cerhan, James R."
3,102 results on '"Cerhan, James R."'

2. DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas

Author

Hopper, Melissa A., Dropik, Abigail R., Walker, Janek S., Novak, Joseph P., Laverty, Miranda S., Manske, Michelle K., Wu, Xiaosheng, Wenzl, Kerstin, Krull, Jordan E., Sarangi, Vivekananda, Maurer, Matthew J., Yang, Zhi-Zhang, Del Busso, Miles D., Habermann, Thomas M., Link, Brian K., Rimsza, Lisa M., Witzig, Thomas E., Ansell, Stephen M., Cerhan, James R., Jevremovic, Dragan, and Novak, Anne J.

Published
2024
Full Text
View/download PDF

3. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

Author

Stokes, Matthew E., Wenzl, Kerstin, Huang, C. Chris, Ortiz, María, Hsu, Chih-Chao, Maurer, Matthew J., Stong, Nicholas, Nakayama, Yumi, Wu, Lei, Chiu, Hsiling, Polonskaia, Ann, Danziger, Samuel A., Towfic, Fadi, Parker, Joel, King, Rebecca L., Link, Brian K., Slager, Susan L., Sarangi, Vivekananda, Asmann, Yan W., Novak, Joseph P., Sudhindra, Akshay, Ansell, Stephen M., Habermann, Thomas M., Hagner, Patrick R., Nowakowski, Grzegorz S., Cerhan, James R., Novak, Anne J., and Gandhi, Anita K.

Published
2024
Full Text
View/download PDF

4. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL

Author

Wenzl, Kerstin, Stokes, Matthew E., Novak, Joseph P., Bock, Allison M., Khan, Sana, Hopper, Melissa A., Krull, Jordan E., Dropik, Abigail R., Walker, Janek S., Sarangi, Vivekananda, Mwangi, Raphael, Ortiz, Maria, Stong, Nicholas, Huang, C. Chris, Maurer, Matthew J., Rimsza, Lisa, Link, Brian K., Slager, Susan L., Asmann, Yan, Mondello, Patrizia, Morin, Ryan, Ansell, Stephen M., Habermann, Thomas M., Witzig, Thomas E., Feldman, Andrew L., King, Rebecca L., Nowakowski, Grzegorz, Cerhan, James R., Gandhi, Anita K., and Novak, Anne J.

Published
2024
Full Text
View/download PDF

6. Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature

Author

Bommier, Côme, Link, Brian K., Gysbers, Brianna J., Maurer, Matthew J., Larson, Melissa C., Khurana, Arushi, Wang, Yucai, Thompson, Carrie A., Chihara, Dai, Alderuccio, Juan P., Koff, Jean L., Epperla, Narendranath, Conconi, Annarita, Lossos, Izidore S., Nowakowski, Grzegorz S., Feldman, Andrew L., Habermann, Thomas M., King, Rebecca L., and Cerhan, James R.

Published
2024
Full Text
View/download PDF

8. Defining primary refractory large B-cell lymphoma

Author

Bock, Allison M., Mwangi, Raphael, Wang, Yucai, Khurana, Arushi, Maurer, Matthew J., Ayers, Amy, Kahl, Brad S., Martin, Peter, Cohen, Jonathon B., Casulo, Carla, Lossos, Izidore S., Farooq, Umar, Ayyappan, Sabarish, Reicks, Tanner, Habermann, Thomas M., Witzig, Thomas E., Flowers, Christopher R., Cerhan, James R., Nastoupil, Loretta J., and Nowakowski, Grzegorz S.

Published
2024
Full Text
View/download PDF

9. Relationship among three common hematological premalignant conditions

Author

Boddicker, Nicholas J., Parikh, Sameer A., Norman, Aaron D., Rabe, Kari G., Griffin, Rosalie, Call, Timothy G., Robinson, Dennis P., Olson, Janet E., Dispenzieri, Angela, Rajkumar, Vincent, Kumar, Shaji, Kay, Neil E., Hanson, Curtis A., Cerhan, James R., Murray, David, Braggio, Esteban, Shanafelt, Tait D., Vachon, Celine M., and Slager, Susan L.

Published
2023
Full Text
View/download PDF

10. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment

Author

Arcaini, Luca, Bommier, Côme, Alderuccio, Juan Pablo, Merli, Michele, Fabbri, Nicole, Nizzoli, Maria Elena, Maurer, Matthew J., Tarantino, Vittoria, Ferrero, Simone, Rattotti, Sara, Talami, Annalisa, Murru, Roberta, Khurana, Arushi, Mwangi, Raphael, Deodato, Marina, Cencini, Emanuele, Re, Francesca, Visco, Carlo, Feldman, Andrew L., Link, Brian K., Delamain, Marcia Torresan, Spina, Michele, Annibali, Ombretta, Pulsoni, Alessandro, Ferreri, Andrés J.M., Stelitano, Caterina Cecilia, Pennese, Elsa, Habermann, Thomas M., Marcheselli, Luigi, Han, Sunwoo, Reis, Isildinha M., Paulli, Marco, Lossos, Izidore S., Cerhan, James R., and Luminari, Stefano

Published
2024
Full Text
View/download PDF

12. Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis

Author

Kleinstern, Geffen, Boddicker, Nicholas J., O’Brien, Daniel R., Allmer, Cristine, Rabe, Kari G., Norman, Aaron D., Griffin, Rosalie, Yan, Huihuang, Ma, Tao, Call, Timothy G., Bruins, Laura, Brown, Sochilt, Bonolo de Campos, Cecilia, Hanson, Curtis A., Leis, Jose F., Ding, Wei, Vachon, Celine M., Kay, Neil E., Oakes, Christopher C., Parker, Alexander S., Brander, Danielle M., Weinberg, J. Brice, Furman, Richard R., Shanafelt, Tait D., Cerhan, James R., Parikh, Sameer A., Braggio, Esteban, and Slager, Susan L.

Published
2024
Full Text
View/download PDF

13. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

Author

Bantilan, Kurt S., Smith, Alexandra N., Maurer, Matthew J., Teruya-Feldstein, Julie, Matasar, Matthew J., Moskowitz, Alison J., Straus, David J., Noy, Ariela, Palomba, M. Lia, Horwitz, Steven M., Hamlin, Paul A., Portlock, Carol S., Cerhan, James R., Habermann, Thomas M., Salles, Gilles A., Nowakowski, Grzegorz S., Moskowitz, Craig H., and Zelenetz, Andrew D.

Published
2024
Full Text
View/download PDF

14. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans

Author

Kleinstern, Geffen, Weinberg, J Brice, Parikh, Sameer A, Braggio, Esteban, Achenbach, Sara J, Robinson, Dennis P, Norman, Aaron D, Rabe, Kari G, Boddicker, Nicholas J, Vachon, Celine M, Lesnick, Connie E, Call, Timothy G, Brander, Danielle M, Rassenti, Laura Z, Kipps, Thomas J, Olson, Janet E, Cerhan, James R, Kay, Neil E, Furman, Richard R, Hanson, Curtis A, Shanafelt, Tait D, and Slager, Susan L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Hematology, Lymphoma, Cancer, Prevention, Clinical Research, Rare Diseases, Adult, Black or African American, Aged, Aged, 80 and over, B-Lymphocytes, Biomarkers, Tumor, Case-Control Studies, Clone Cells, Female, Follow-Up Studies, Humans, Immunoglobulins, Immunophenotyping, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytosis, Male, Middle Aged, Prognosis, Risk Factors, United States, White People, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Monoclonal B-cell lymphocytosis (MBL) is a precursor to CLL. Other than age, sex, and CLL family-history, little is known about factors associated with MBL risk. A polygenic-risk-score (PRS) of 41 CLL-susceptibility variants has been found to be associated with CLL risk among individuals of European-ancestry(EA). Here, we evaluate these variants, the PRS, and environmental factors for MBL risk. We also evaluate these variants and the CLL-PRS among African-American (AA) and EA-CLL cases and controls. Our study included 560 EA MBLs, 869 CLLs (696 EA/173 AA), and 2866 controls (2631 EA/235 AA). We used logistic regression, adjusting for age and sex, to estimate odds ratios (OR) and 95% confidence intervals within each race. We found significant associations with MBL risk among 21 of 41 variants and with the CLL-PRS (OR = 1.86, P = 1.9 × 10-29, c-statistic = 0.72). Little evidence of any association between MBL risk and environmental factors was observed. We observed significant associations of the CLL-PRS with EA-CLL risk (OR = 2.53, P = 4.0 × 10-63, c-statistic = 0.77) and AA-CLL risk (OR = 1.76, P = 5.1 × 10-5, c-statistic = 0.62). Inherited genetic factors and not environmental are associated with MBL risk. In particular, the CLL-PRS is a strong predictor for both risk of MBL and EA-CLL, but less so for AA-CLL supporting the need for further work in this population.

Published
2022

15. Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments

Author

Krull, Jordan E., Wenzl, Kerstin, Hopper, Melissa A., Manske, Michelle K., Sarangi, Vivekananda, Maurer, Matthew J., Larson, Melissa C., Mondello, Patrizia, Yang, ZhiZhang, Novak, Joseph P., Serres, Makayla, Whitaker, Kaitlyn R., Villasboas Bisneto, Jose C., Habermann, Thomas M., Witzig, Thomas E., Link, Brian K., Rimsza, Lisa M., King, Rebecca L., Ansell, Stephen M., Cerhan, James R., and Novak, Anne J.

Published
2024
Full Text
View/download PDF

17. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Author

Bock, Allison M., Gile, Jennifer J., Larson, Melissa C., Poonsombudlert, Kittika, Tawfiq, Reema K., Maliske, Seth, Maurer, Matthew J., Kabat, Brian F., Paludo, Jonas, Inwards, David J., Ayyappan, Sabarish, Link, Brian K., Ansell, Stephen M., Habermann, Thomas M., Witzig, Thomas E., Nowakowski, Grzegorz S., Cerhan, James R., Farooq, Umar, and Wang, Yucai

Published
2023
Full Text
View/download PDF

19. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival

Author

Goldman, Max L, Mao, Jimmy J, Strouse, Christopher S, Chen, Wanqi, Rupji, Manali, Chen, Zhengjia, Maurer, Matthew J, Calzada, Oscar, Churnetski, Michael, Flowers, Christopher R, Cerhan, James R, Link, Brian K, Thompson, Carrie A, and Cohen, Jonathon B

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Lymphoma, Hematology, Genetics, Clinical Research, Rare Diseases, Cancer, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Diagnostic Imaging, Humans, Lymphoma, Follicular, Neoplasm Recurrence, Local, Positron-Emission Tomography, Remission Induction, Retrospective Studies, computed tomography, follicular lymphoma, positron emission tomography-computed tomography, relapsed follicular lymphoma, surveillance, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundAlthough many patients with follicular lymphoma (FL) undergo routine radiographic surveillance during their first remission, no consensus exists on the modality, duration, frequency, or need for routine imaging studies. The authors retrospectively examined the effect of surveillance imaging on relapse detection and overall survival (OS) in patients with FL.MethodsPatients with newly diagnosed FL who had a response to induction therapy were identified from the Lymphoid Malignancies Enterprise Architecture Database (LEAD) at Emory University and from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic. Patients were evaluated for both relapse and method of relapse detection (ie, clinical concerns vs radiologic detection through surveillance imaging in an asymptomatic patient).ResultsOf 148 patients in the LEAD cohort, 55 (37%) relapsed, and the majority (n = 35; 64%) of relapses were detected clinically. In the MER cohort, 63 of 177 relapses (54%) were detected clinically. There was no significant difference in OS from the date of diagnosis between the 2 methods of relapse detection in the LEAD (hazard ratio [HR], 0.61; 95% CI, 0.13-2.94; P = .54) and MER (HR, 1.02; 95% CI, 0.47-2.21; P = .96) cohorts. Similarly, there was no significant difference in OS from the date of relapse between the 2 methods of relapse detection in the LEAD (HR, 0.47; 95% CI, 0.10-2.27; P = .35) and MER (HR, 1.02; 95% CI, 0.47-2.21; P = .96) cohorts.ConclusionsThese findings suggest a limited role for routine surveillance imaging in patients with FL who complete front-line therapy. Future studies should evaluate which patients may benefit from a more aggressive surveillance approach and should explore novel methods of relapse detection.

Published
2021

20. Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer.

Author

Besson, Caroline, Moore, Amy, Wu, Wenting, Vajdic, Claire M, de Sanjose, Silvia, Camp, Nicola J, Smedby, Karin E, Shanafelt, Tait D, Morton, Lindsay M, Brewer, Jerry D, Zablotska, Lydia, Engels, Eric A, Cerhan, James R, Slager, Susan L, Han, Jiali, and Berndt, Sonja I

Subjects
Lymphoma, Clinical Research, Cancer, Hematology, Rare Diseases, Genetics, Prevention, 2.1 Biological and endogenous factors, Aetiology, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Polymorphism, Single Nucleotide, Risk Factors, Skin Neoplasms, CLL, NMSC, polygenic risk score, pleiotropy, InterLymph Consortium. Full authors list is given at the end of the manuscript, Statistics, Public Health and Health Services, Epidemiology
Abstract

BackgroundEpidemiological studies have demonstrated a positive association between chronic lymphocytic leukaemia (CLL) and non-melanoma skin cancer (NMSC). We hypothesized that shared genetic risk factors between CLL and NMSC could contribute to the association observed between these diseases.MethodsWe examined the association between (i) established NMSC susceptibility loci and CLL risk in a meta-analysis including 3100 CLL cases and 7667 controls and (ii) established CLL loci and NMSC risk in a study of 4242 basal cell carcinoma (BCC) cases, 825 squamous cell carcinoma (SCC) cases and 12802 controls. Polygenic risk scores (PRS) for CLL, BCC and SCC were constructed using established loci. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).ResultsHigher CLL-PRS was associated with increased BCC risk (OR4th-quartile-vs-1st-quartile = 1.13, 95% CI: 1.02-1.24, Ptrend = 0.009), even after removing the shared 6p25.3 locus. No association was observed with BCC-PRS and CLL risk (Ptrend = 0.68). These findings support a contributory role for CLL in BCC risk, but not for BCC in CLL risk. Increased CLL risk was observed with higher SCC-PRS (OR4th-quartile-vs-1st-quartile = 1.22, 95% CI: 1.08-1.38, Ptrend = 1.36 × 10-5), which was driven by shared genetic susceptibility at the 6p25.3 locus.ConclusionThese findings highlight the role of pleiotropy regarding the pathogenesis of CLL and NMSC and shows that a single pleiotropic locus, 6p25.3, drives the observed association between genetic susceptibility to SCC and increased CLL risk. The study also provides evidence that genetic susceptibility for CLL increases BCC risk.

Published
2021

23. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL

Author

Griffin, Rosalie, Wiedmeier-Nutor, Julia E., Parikh, Sameer A., McCabe, Chantal E., O'Brien, Daniel R., Boddicker, Nicholas J., Kleinstern, Geffen, Rabe, Kari G., Bruins, Laura, Brown, Sochilt, Bonolo de Campos, Cecilia, Ding, Wei, Leis, Jose F., Hampel, Paul J., Call, Timothy G., Van Dyke, Daniel L., Kay, Neil E., Cerhan, James R., Yan, Huihuang, Slager, Susan L., and Braggio, Esteban

Published
2023
Full Text
View/download PDF

24. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Author

Epperla, Narendranath, Switchenko, Jeffrey, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Gordon, Max J., Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Sawalha, Yazeed, Hill, Brian T., Ghosh, Nilanjan, Park, Steven I., Bond, David A., Hamadani, Mehdi, Fenske, Timothy S., Martin, Peter, Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Link, Brian K., Kaplan, Lawrence D., Inwards, David J., Feldman, Andrew L., Hsi, Eric D., Maddocks, Kami, Blum, Kristie A., Bartlett, Nancy L., Cerhan, James R., Leonard, John P., Habermann, Thomas M., Maurer, Matthew J., and Cohen, Jonathon B.

Published
2023
Full Text
View/download PDF

25. The association between genetically elevated polyunsaturated fatty acids and risk of cancer

Author

Tintle, Nathan, Rice, Terri, Cheng, Iona, Jenkins, Mark, Gallinger, Steve, Cornish, Alex J., Sud, Amit, Vijayakrishnan, Jayaram, Wrensch, Margaret, Johansson, Mattias, Norman, Aaron D., Klein, Alison, Clay-Gilmour, Alyssa, Franke, Andre, Ardisson Korat, Andres V., Wheeler, Bill, Nilsson, Björn, Smith, Caren, Heng, Chew-Kiat, Song, Ci, Riadi, David, Claus, Elizabeth B., Ellinghaus, Eva, Ostroumova, Evgenia, Hosnijeh, de Vathaire, Florent, Cugliari, Giovanni, Matullo, Giuseppe, Oi-Lin Ng, Irene, Passow, Jeanette E., Foo, Jia Nee, Han, Jiali, Liu, Jianjun, Barnholtz-Sloan, Jill, Schildkraut, Joellen M., Maris, John, Wiemels, Joseph L., Hemminki, Kari, Yang, Keming, Kiemeney, Lambertus A., Wu, Lang, Amundadottir, Laufey, Stern, Marc-Henri, Boutron, Marie-Christine, Iles, Mark Martin, Purdue, Mark P., Stanulla, Martin, Bondy, Melissa, Gaudet, Mia, Mobuchon, Lenha, Camp, Nicola J., Sham, Pak Chung, Guénel, Pascal, Brennan, Paul, Taylor, Philip R., Ostrom, Quinn, Stolzenberg-Solomon, Rachael, Dorajoo, Rajkumar, Houlston, Richard, Jenkins, Robert B., Diskin, Sharon, Berndt, Sonja I., Tsavachidis, Spiridon, Channock, Stephen J., Harrison, Tabitha, Galesloot, Tessel, Gyllensten, Ulf, Joseph, Vijai, Shi, Y., Yang, Wenjian, Lin, Yi, Van Den Eeden, Stephen K., Haycock, Philip C., Borges, Maria Carolina, Burrows, Kimberley, Lemaitre, Rozenn N., Burgess, Stephen, Khankari, Nikhil K., Tsilidis, Konstantinos K., Gaunt, Tom R., Hemani, Gibran, Zheng, Jie, Truong, Therese, Birmann, Brenda M., OMara, Tracy, Spurdle, Amanda B., Iles, Mark M., Law, Matthew H., Slager, Susan L., Saberi Hosnijeh, Fatemeh, Mariosa, Daniela, Cotterchio, Michelle, Cerhan, James R., Peters, Ulrike, Enroth, Stefan, Gharahkhani, Puya, Le Marchand, Loic, Williams, Ann C., Block, Robert C., Amos, Christopher I., Hung, Rayjean J., Zheng, Wei, Gunter, Marc J., Smith, George Davey, Relton, Caroline, and Martin, Richard M.

Published
2023
Full Text
View/download PDF

28. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

Author

Berndt, Sonja I., Vijai, Joseph, Benavente, Yolanda, Camp, Nicola J., Nieters, Alexandra, Wang, Zhaoming, Smedby, Karin E., Kleinstern, Geffen, Hjalgrim, Henrik, Besson, Caroline, Skibola, Christine F., Morton, Lindsay M., Brooks-Wilson, Angela R., Teras, Lauren R., Breeze, Charles, Arias, Joshua, Adami, Hans-Olov, Albanes, Demetrius, Anderson, Kenneth C., Ansell, Stephen M., Bassig, Bryan, Becker, Nikolaus, Bhatti, Parveen, Birmann, Brenda M., Boffetta, Paolo, Bracci, Paige M., Brennan, Paul, Brown, Elizabeth E., Burdett, Laurie, Cannon-Albright, Lisa A., Chang, Ellen T., Chiu, Brian C. H., Chung, Charles C., Clavel, Jacqueline, Cocco, Pierluigi, Colditz, Graham, Conde, Lucia, Conti, David V., Cox, David G., Curtin, Karen, Casabonne, Delphine, De Vivo, Immaculata, Diepstra, Arjan, Diver, W. Ryan, Dogan, Ahmet, Edlund, Christopher K., Foretova, Lenka, Fraumeni, Jr, Joseph F., Gabbas, Attilio, Ghesquières, Hervé, Giles, Graham G., Glaser, Sally, Glenn, Martha, Glimelius, Bengt, Gu, Jian, Habermann, Thomas M., Haiman, Christopher A., Haioun, Corinne, Hofmann, Jonathan N., Holford, Theodore R., Holly, Elizabeth A., Hutchinson, Amy, Izhar, Aalin, Jackson, Rebecca D., Jarrett, Ruth F., Kaaks, Rudolph, Kane, Eleanor, Kolonel, Laurence N., Kong, Yinfei, Kraft, Peter, Kricker, Anne, Lake, Annette, Lan, Qing, Lawrence, Charles, Li, Dalin, Liebow, Mark, Link, Brian K., Magnani, Corrado, Maynadie, Marc, McKay, James, Melbye, Mads, Miligi, Lucia, Milne, Roger L., Molina, Thierry J., Monnereau, Alain, Montalvan, Rebecca, North, Kari E., Novak, Anne J., Onel, Kenan, Purdue, Mark P., Rand, Kristin A., Riboli, Elio, Riby, Jacques, Roman, Eve, Salles, Gilles, Sborov, Douglas W., Severson, Richard K., Shanafelt, Tait D., Smith, Martyn T., Smith, Alexandra, Song, Kevin W., Song, Lei, Southey, Melissa C., Spinelli, John J., Staines, Anthony, Stephens, Deborah, Sutherland, Heather J., Tkachuk, Kaitlyn, Thompson, Carrie A., Tilly, Hervé, Tinker, Lesley F., Travis, Ruth C., Turner, Jenny, Vachon, Celine M., Vajdic, Claire M., Van Den Berg, Anke, Van Den Berg, David J., Vermeulen, Roel C. H., Vineis, Paolo, Wang, Sophia S., Weiderpass, Elisabete, Weiner, George J., Weinstein, Stephanie, Doo, Nicole Wong, Ye, Yuanqing, Yeager, Meredith, Yu, Kai, Zeleniuch-Jacquotte, Anne, Zhang, Yawei, Zheng, Tongzhang, Ziv, Elad, Sampson, Joshua, Chatterjee, Nilanjan, Offit, Kenneth, Cozen, Wendy, Wu, Xifeng, Cerhan, James R., Chanock, Stephen J., Slager, Susan L., and Rothman, Nathaniel

Published
2022
Full Text
View/download PDF

29. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

Author

Berndt, Sonja I., Vijai, Joseph, Benavente, Yolanda, Camp, Nicola J., Nieters, Alexandra, Wang, Zhaoming, Smedby, Karin E., Kleinstern, Geffen, Hjalgrim, Henrik, Besson, Caroline, Skibola, Christine F., Morton, Lindsay M., Brooks-Wilson, Angela R., Teras, Lauren R., Breeze, Charles, Arias, Joshua, Adami, Hans-Olov, Albanes, Demetrius, Anderson, Kenneth C., Ansell, Stephen M., Bassig, Bryan, Becker, Nikolaus, Bhatti, Parveen, Birmann, Brenda M., Boffetta, Paolo, Bracci, Paige M., Brennan, Paul, Brown, Elizabeth E., Burdett, Laurie, Cannon-Albright, Lisa A., Chang, Ellen T., Chiu, Brian C. H., Chung, Charles C., Clavel, Jacqueline, Cocco, Pierluigi, Colditz, Graham, Conde, Lucia, Conti, David V., Cox, David G., Curtin, Karen, Casabonne, Delphine, De Vivo, Immaculata, Diepstra, Arjan, Diver, W. Ryan, Dogan, Ahmet, Edlund, Christopher K., Foretova, Lenka, Fraumeni, Jr, Joseph F., Gabbas, Attilio, Ghesquières, Hervé, Giles, Graham G., Glaser, Sally, Glenn, Martha, Glimelius, Bengt, Gu, Jian, Habermann, Thomas M., Haiman, Christopher A., Haioun, Corinne, Hofmann, Jonathan N., Holford, Theodore R., Holly, Elizabeth A., Hutchinson, Amy, Izhar, Aalin, Jackson, Rebecca D., Jarrett, Ruth F., Kaaks, Rudolph, Kane, Eleanor, Kolonel, Laurence N., Kong, Yinfei, Kraft, Peter, Kricker, Anne, Lake, Annette, Lan, Qing, Lawrence, Charles, Li, Dalin, Liebow, Mark, Link, Brian K., Magnani, Corrado, Maynadie, Marc, McKay, James, Melbye, Mads, Miligi, Lucia, Milne, Roger L., Molina, Thierry J., Monnereau, Alain, Montalvan, Rebecca, North, Kari E., Novak, Anne J., Onel, Kenan, Purdue, Mark P., Rand, Kristin A., Riboli, Elio, Riby, Jacques, Roman, Eve, Salles, Gilles, Sborov, Douglas W., Severson, Richard K., Shanafelt, Tait D., Smith, Martyn T., Smith, Alexandra, Song, Kevin W., Song, Lei, Southey, Melissa C., Spinelli, John J., Staines, Anthony, Stephens, Deborah, Sutherland, Heather J., Tkachuk, Kaitlyn, Thompson, Carrie A., Tilly, Hervé, Tinker, Lesley F., Travis, Ruth C., Turner, Jenny, Vachon, Celine M., Vajdic, Claire M., Van Den Berg, Anke, Van Den Berg, David J., Vermeulen, Roel C. H., Vineis, Paolo, Wang, Sophia S., Weiderpass, Elisabete, Weiner, George J., Weinstein, Stephanie, Doo, Nicole Wong, Ye, Yuanqing, Yeager, Meredith, Yu, Kai, Zeleniuch-Jacquotte, Anne, Zhang, Yawei, Zheng, Tongzhang, Ziv, Elad, Sampson, Joshua, Chatterjee, Nilanjan, Offit, Kenneth, Cozen, Wendy, Wu, Xifeng, Cerhan, James R., Chanock, Stephen J., Slager, Susan L., and Rothman, Nathaniel

Published
2023
Full Text
View/download PDF

30. Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes

Author

Din, Lennox, Sheikh, Mohammad, Kosaraju, Nikitha, Smedby, Karin Ekstrom, Bernatsky, Sasha, Berndt, Sonja I, Skibola, Christine F, Nieters, Alexandra, Wang, Sophia, McKay, James D, Cocco, Pierluigi, Maynadié, Marc, Foretová, Lenka, Staines, Anthony, Mack, Thomas M, de Sanjosé, Silvia, Vyse, Timothy J, Padyukov, Leonid, Monnereau, Alain, Arslan, Alan A, Moore, Amy, Brooks‐Wilson, Angela R, Novak, Anne J, Glimelius, Bengt, Birmann, Brenda M, Link, Brian K, Stewart, Carolyn, Vajdic, Claire M, Haioun, Corinne, Magnani, Corrado, Conti, David V, Cox, David G, Casabonne, Delphine, Albanes, Demetrius, Kane, Eleanor, Roman, Eve, Muzi, Giacomo, Salles, Gilles, Giles, Graham G, Adami, Hans‐Olov, Ghesquières, Hervé, De Vivo, Immaculata, Clavel, Jacqueline, Cerhan, James R, Spinelli, John J, Hofmann, Jonathan, Vijai, Joseph, Curtin, Karen, Costenbader, Karen H, Onel, Kenan, Offit, Kenneth, Teras, Lauren R, Morton, Lindsay, Conde, Lucia, Miligi, Lucia, Melbye, Mads, Ennas, Maria Grazia, Liebow, Mark, Purdue, Mark P, Glenn, Martha, Southey, Melissa C, Din, Morris, Rothman, Nathaniel, Camp, Nicola J, Doo, Nicole Wong, Becker, Nikolaus, Pradhan, Nisha, Bracci, Paige M, Boffetta, Paolo, Vineis, Paolo, Brennan, Paul, Kraft, Peter, Lan, Qing, Severson, Richard K, Vermeulen, Roel CH, Milne, Roger L, Kaaks, Rudolph, Travis, Ruth C, Weinstein, Stephanie J, Chanock, Stephen J, Ansell, Stephen M, Slager, Susan L, Zheng, Tongzhang, Zhang, Yawei, Benavente, Yolanda, Taub, Zachary, Madireddy, Lohith, Gourraud, Pierre‐Antoine, Oksenberg, Jorge R, Cozen, Wendy, Hjalgrim, Henrik, and Khankhanian, Pouya

Subjects
Biological Sciences, Genetics, Lymphoma, Arthritis, Neurodegenerative, Brain Disorders, Autoimmune Disease, Cancer, Human Genome, Rare Diseases, Hematology, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Alleles, Autoimmune Diseases, Female, Genetic Predisposition to Disease, HLA Antigens, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Risk Factors, autoimmune disease, genome-wide association study, meta-analysis, non-Hodgkin lymphoma, Public Health and Health Services, Epidemiology
Abstract

Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta-analysis. Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta-analysis (combing AD with NHL) implicated genes of apoptosis and telomere length. This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.

Published
2019

31. Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis

Author

Cerhan, James R, Kane, Eleanor, Vajdic, Claire M, Linet, Martha S, Monnereau, Alain, Bernstein, Leslie, de Sanjose, Silvia, Chiu, Brian C-H, Spinelli, John J, Dal Maso, L, Zhang, Yawei, Larrabee, Beth R, Cozen, Wendy, Smith, Alexandra G, Clavel, Jacqueline, Serraino, Diego, Zheng, Tongzhang, Holly, Elizabeth A, Weisenberger, Dennis D, Slager, Susan L, and Bracci, Paige M

Subjects
Epidemiology, Biomedical and Clinical Sciences, Public Health, Health Sciences, Lymphoma, Prevention, Rare Diseases, Hematology, Cancer, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Blood Transfusion, Case-Control Studies, Female, Humans, Logistic Models, Lymphoma, Non-Hodgkin, Male, Middle Aged, Odds Ratio, Risk Factors, Young Adult, Transfusion, Etiology, Pooled analysis, Oncology and Carcinogenesis, Public Health and Health Services, Oncology and carcinogenesis
Abstract

PurposeTo conduct a pooled analysis assessing the association of blood transfusion with risk of non-Hodgkin lymphoma (NHL).MethodsWe used harmonized data from 13 case-control studies (10,805 cases, 14,026 controls) in the InterLymph Consortium. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using unconditional logistic regression, adjusted for study design variables.ResultsAmong non-Hispanic whites (NHW), history of any transfusion was inversely associated with NHL risk for men (OR 0.74; 95% CI 0.65-0.83) but not women (OR 0.92; 95% CI 0.83-1.03), pheterogeneity = 0.014. Transfusion history was not associated with risk in other racial/ethnic groups. There was no trend with the number of transfusions, time since first transfusion, age at first transfusion, or decade of first transfusion, and further adjustment for socioeconomic status, body mass index, smoking, alcohol use, and HCV seropositivity did not alter the results. Associations for NHW men were stronger in hospital-based (OR 0.56; 95% CI 0.45-0.70) but still apparent in population-based (OR 0.84; 95% CI 0.72-0.98) studies.ConclusionsIn the setting of a literature reporting mainly null and some positive associations, and the lack of a clear methodologic explanation for our inverse association restricted to NHW men, the current body of evidence suggests that there is no association of blood transfusion with risk of NHL.

Published
2019

32. Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma

Author

Hill, Brian T, Nastoupil, Loretta, Winter, Allison M, Becnel, Melody R, Cerhan, James R, Habermann, Thomas M, Link, Brian K, Maurer, Matthew J, Fakhri, Bita, Reddy, Prathima, Smith, Stephen D, Mukhija, Dhruvika, Jagadeesh, Deepa, Desai, Amrita, Alderuccio, Juan Pablo, Lossos, Izidore S, Mehra, Pooja, Portell, Craig A, Goldman, Max L, Calzada, Oscar, Cohen, Jonathon B, Hussain, Mohammad J, Ghosh, Nilanjan, Caimi, Paolo, Tiutan, Timothy, Martin, Peter, Kodali, Abhigna, Evens, Andrew M, and Kahl, Brad S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Cancer, Rare Diseases, Clinical Research, Lymphoma, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Humans, Lymphoma, Follicular, Maintenance Chemotherapy, Male, Middle Aged, Prednisone, Retrospective Studies, Rituximab, Survival Rate, Vincristine, follicular lymphoma, bendamustine, rituximab, maintenance, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.

Published
2019

34. Rates of Asymptomatic COVID-19 Infection and Associated Factors in Olmsted County, Minnesota, in the Prevaccination Era

Author

Vachon, Celine M., Norman, Aaron D., Prasad, Kavita, Jensen, Dan, Schaeferle, Gavin M., Vierling, Kristy L., Sherden, Meaghan, Majerus, Michelle R., Bews, Katherine A., Heinzen, Ethan P., Hebl, Amy, Yost, Kathleen J., Kennedy, Richard B., Theel, Elitza S., Ghosh, Aditya, Fries, Meghan, Wi, Chung-Il, Juhn, Young J., Sampathkumar, Priya, Morice, William G., II, Rocca, Walter A., Tande, Aaron J., Cerhan, James R., Limper, Andrew H., Ting, Henry H., Farrugia, Gianrico, Carter, Rickey E., Finney Rutten, Lila J., Jacobson, Robert M., and St. Sauver, Jennifer

Published
2022
Full Text
View/download PDF

37. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study

Author

Tun, Aung M., Khurana, Arushi, Mwangi, Raphael, Link, Brian K., Wang, Yucai, Feldman, Andrew L., Thompson, Carrie A., Novak, Anne J., Villasboas, Jose C., Thanarajasingam, Gita, Farooq, Umar, Syrbu, Sergei, Nowakowski, Grzegorz S., Witzig, Thomas E., Ansell, Stephen M., Rimsza, Lisa M., Cerhan, James R., Habermann, Thomas M., and Maurer, Matthew J.

Published
2022
Full Text
View/download PDF

41. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes

Author

Castellino, Alessia, Wang, Yucai, Larson, Melissa C., Maurer, Matthew J., Link, Brian K., Farooq, Umar, Feldman, Andrew L., Syrbu, Sergei I., Habermann, Thomas M., Paludo, Jonas, Inwards, David J., Witzig, Thomas E., Ansell, Stephen M., Allmer, Cristine, Slager, Susan L., Cohen, Jonathon B., Martin, Peter, Cerhan, James R., and Nowakowski, Grzegorz S.

Published
2022
Full Text
View/download PDF

47. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Author

Abro, Brooj, Maurer, Matthew J., Habermann, Thomas M., Burack, W. Richard, Chapman, Jennifer R., Cohen, Jonathon B., Friedberg, Jonathan W., Inghirami, Giorgio, Kahl, Brad S., Larson, Melissa C., Link, Brian K., Lossos, Izidore S., Martin, Peter, McDonnell, Timothy J., Nastoupil, Loretta J., Riska, Shaun M., Syrbu, Sergei, Vega, Francisco, Vij, Kiran R., Flowers, Christopher R., Cerhan, James R., Jaye, David L., and Feldman, Andrew L.

Abstract

Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will affect <1% of non-Hodgkin lymphomas.

Published
2024
Full Text
View/download PDF

48. Stratifying heart failure patients with graph neural network and transformer using Electronic Health Records to optimize drug response prediction.

Author

Chowdhury, Shaika, Chen, Yongbin, Li, Pengyang, Rajaganapathy, Sivaraman, Wen, Andrew, Ma, Xiao, Dai, Qiying, Yu, Yue, Fu, Sunyang, Jiang, Xiaoqian, He, Zhe, Sohn, Sunghwan, Liu, Xiaoke, Bielinski, Suzette J, Chamberlain, Alanna M, Cerhan, James R, and Zong, Nansu

Abstract

Objectives Heart failure (HF) impacts millions of patients worldwide, yet the variability in treatment responses remains a major challenge for healthcare professionals. The current treatment strategies, largely derived from population based evidence, often fail to consider the unique characteristics of individual patients, resulting in suboptimal outcomes. This study aims to develop computational models that are patient-specific in predicting treatment outcomes, by utilizing a large Electronic Health Records (EHR) database. The goal is to improve drug response predictions by identifying specific HF patient subgroups that are likely to benefit from existing HF medications. Materials and Methods A novel, graph-based model capable of predicting treatment responses, combining Graph Neural Network and Transformer was developed. This method differs from conventional approaches by transforming a patient's EHR data into a graph structure. By defining patient subgroups based on this representation via K-Means Clustering, we were able to enhance the performance of drug response predictions. Results Leveraging EHR data from 11 627 Mayo Clinic HF patients, our model significantly outperformed traditional models in predicting drug response using NT-proBNP as a HF biomarker across five medication categories (best RMSE of 0.0043). Four distinct patient subgroups were identified with differential characteristics and outcomes, demonstrating superior predictive capabilities over existing HF subtypes (best mean RMSE of 0.0032). Discussion These results highlight the power of graph-based modeling of EHR in improving HF treatment strategies. The stratification of patients sheds light on particular patient segments that could benefit more significantly from tailored response predictions. Conclusions Longitudinal EHR data have the potential to enhance personalized prognostic predictions through the application of graph-based AI techniques. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations.

Author

Wiedmeier-Nutor, J. Erin, McCabe, Chantal E., O'Brien, Daniel R., Jessen, Erik, Bonolo de Campos, Cecilia, Boddicker, Nicholas J., Griffin, Rosalie, Allmer, Cristine, Rabe, Kari G., Cerhan, James R., Parikh, Sameer A., Kay, Neil E., Yan, Huihuang, Van Dyke, Daniel L., Slager, Susan L., and Braggio, Esteban

Subjects
CHRONIC lymphocytic leukemia diagnosis, CHRONIC lymphocytic leukemia, RESEARCH funding, CHROMOSOME abnormalities, DESCRIPTIVE statistics, LONGITUDINAL method, KARYOTYPES, FLUORESCENCE in situ hybridization, GENETIC mutation, GENETIC techniques, SEQUENCE analysis, GENOMES, SENSITIVITY & specificity (Statistics)
Abstract

Simple Summary: Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow, commonly affecting older adults. Most CLL patients have an abnormal copy number of chromosomes that are used for risk stratification. Chromosomal copy number changes have been evaluated using a technique called Fluorescence in situ hybridization (FISH). Next-generation sequencing (NGS) is now common practice in many cancers and in addition to DNA mutations, can also identify genetic copy number alterations. Together, these could inform disease prognosis and guide decisions on treatment. This study evaluated NGS as an alternative method to FISH for detecting clinically relevant chromosomal copy number changes in CLL. Chronic lymphocytic leukemia (CLL) is characterized by multiple copy number alterations (CNAs) and somatic mutations that are central to disease prognosis, risk stratification, and mechanisms of therapy resistance. Fluorescence in situ hybridization (FISH) panels are widely used in clinical applications as the gold standard for screening prognostic chromosomal abnormalities in CLL. DNA sequencing is an alternative approach to identifying CNAs but is not an established method for clinical CNA screening. We sequenced DNA from 509 individuals with CLL or monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, using a targeted sequencing panel of 59 recurrently mutated genes in CLL and additional amplicons across regions affected by clinically relevant CNAs [i.e., del(17p), del(11q), del(13q), and trisomy 12]. We used the PatternCNV algorithm to call CNA and compared the concordance of calling clinically relevant CNAs by targeted sequencing to that of FISH. We found a high accuracy of calling CNAs via sequencing compared to FISH. With FISH as the gold standard, the specificity of targeted sequencing was >95%, sensitivity was >86%, positive predictive value was >90%, and negative predictive value was >84% across the clinically relevant CNAs. Using targeted sequencing, we were also able to identify other common CLL-associated CNAs, including del(6q), del(14q), and gain 8q, as well as complex karyotype, defined as the presence of 3 or more chromosomal abnormalities, in 26 patients. In a single and cost-effective assay that can be performed on stored DNA samples, targeted sequencing can simultaneously detect CNAs, somatic mutations, and complex karyotypes, which are all important prognostic features in CLL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results